{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:48Z","timestamp":1790958288373,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.autrev.2020.102645","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T21:51:41Z","timestamp":1597269101000},"page":"102645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis"],"prefix":"10.1016","volume":"19","author":[{"given":"Ruihe","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102645_bb0005","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"issue":"10055","key":"10.1016\/j.autrev.2020.102645_bb0010","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.autrev.2020.102645_bb0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopha.2016.02.001","article-title":"Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis","volume":"79","author":"Kumar","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2020.102645_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gene.2019.03.033","article-title":"Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review","volume":"702","author":"Karami","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.autrev.2020.102645_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2017.04.005","article-title":"Lessons learned from twins in autoimmune and chronic inflammatory diseases","volume":"83","author":"Generali","year":"2017","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102645_bb0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrrheum.2012.134","article-title":"Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis","volume":"8","author":"Arend","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"102369","key":"10.1016\/j.autrev.2020.102645_bb0040","article-title":"Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases","volume":"18","author":"Benedettoa","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"102397","key":"10.1016\/j.autrev.2020.102645_bb0045","article-title":"Macrophage M1\/M2 polarization and rheumatoid arthritis: a systematic review","volume":"18","author":"Tardito","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0050","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"7639","key":"10.1016\/j.autrev.2020.102645_bb0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrrheum.2012.149","article-title":"T cells out of control--impaired immune regulation in the inflamed joint","volume":"9","author":"Wehrens","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"23","key":"10.1016\/j.autrev.2020.102645_bb0070","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102645_bb0080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/apm.12399","article-title":"Elevated circulating Th17 and follicular helper CD4(+) T cells in patients with rheumatoid arthritis","volume":"123","author":"Zhang","year":"2015","journal-title":"APMIS"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","volume":"39","author":"Derksen","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2020.102645_bb0090","article-title":"Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: a comprehensive review","volume":"102469","author":"Lee","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0095","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.clinthera.2019.04.028","article-title":"The natural history of rheumatoid arthritis","volume":"41","author":"Deane","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2020.102645_bb0100","article-title":"Antigen-specific immunotherapies in rheumatic diseases","author":"Pozsgay","year":"2017","journal-title":"Nat Rev"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0105","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/eji.200526000","article-title":"Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis","volume":"35","author":"Burkhardt","year":"2005","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0110","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","article-title":"Th17 and regulatory T cells in mediating and restraining inflammation","volume":"140","author":"Littman","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0115","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102645_bb0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4+Foxp3+ regulatory T cells in immune tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/intimm\/dxv079","article-title":"T follicular helper cells, T follicular regulatory cells and autoimmunity","volume":"28","author":"Zhu","year":"2016","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2020.102645_bb0130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00296-010-1710-0","article-title":"The Th17\/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis","volume":"32","author":"Wang","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10238-018-0530-5","article-title":"Imbalance of circulating Tfr\/Tfh ratio in patients with rheumatoid arthritis","volume":"19","author":"Wang","year":"2018","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2020.102645_bb0140","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102645_bb0145","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2020.102645_bb0155","doi-asserted-by":"crossref","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Science Immunology"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.autrev.2020.102645_bb0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J Autoimmun"},{"issue":"22","key":"10.1016\/j.autrev.2020.102645_bb0170","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose Interleukin-2 in HCV-induced Vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"issue":"179","key":"10.1016\/j.autrev.2020.102645_bb0175","doi-asserted-by":"crossref","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.1016\/j.autrev.2020.102645_bb0180","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0185","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4257","key":"10.1016\/j.autrev.2020.102645_bb0195","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from Normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"issue":"4856","key":"10.1016\/j.autrev.2020.102645_bb0200","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0205","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.4049\/jimmunol.120.6.2027","article-title":"Smith Ka. T cell growth factor: parameters of production and a quantitative microassay for activity","volume":"120","author":"Gillis","year":"1978","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: a transcription factor comes of age","volume":"10","author":"Muller","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0220","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cytogfr.2006.07.003","article-title":"Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system","volume":"17","author":"Kim","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0225","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.immuni.2009.06.021","article-title":"Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses","volume":"31","author":"Kallies","year":"2009","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cell.2006.07.005","article-title":"FOXP3 and NFAT: partners in tolerance","volume":"126","author":"Rudensky","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2020.102645_bb0240","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.1117893","article-title":"Structure of the quaternary complex of interleukin-2 with its \u03b1, \u03b2, and \u03b3c receptors","volume":"310","author":"Wang","year":"2005","journal-title":"Science"},{"issue":"311","key":"10.1016\/j.autrev.2020.102645_bb0245","doi-asserted-by":"crossref","first-page":"311ra170","DOI":"10.1126\/scitranslmed.aac8155","article-title":"IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy","volume":"7","author":"Su","year":"2015","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0250","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u03b3c family of cytokines: basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"5\u20136","key":"10.1016\/j.autrev.2020.102645_bb0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"23","key":"10.1016\/j.autrev.2020.102645_bb0265","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0270","first-page":"262","article-title":"A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2","volume":"100","author":"Rosenberg","year":"1986","journal-title":"Surgery."},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0275","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"issue":"15","key":"10.1016\/j.autrev.2020.102645_bb0280","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102645_bb0285","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","article-title":"Ulcerative colitis-like disease in mice with a disrupted Interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity."},{"issue":"10","key":"10.1016\/j.autrev.2020.102645_bb0295","doi-asserted-by":"crossref","first-page":"18574","DOI":"10.3390\/ijms151018574","article-title":"Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity","volume":"15","author":"Kosmaczewska","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0300","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102645_bb0305","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6070067","article-title":"The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid Arthritis","volume":"6","author":"Kotake","year":"2017","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0315","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0320","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"de Morales JMG","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102645_bb0325","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1073\/pnas.1035999100","article-title":"IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist","volume":"100","author":"Nakae","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102645_bb0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fimmu.2019.00209","article-title":"Specific inhibition of soluble gammac receptor attenuates collagen-induced arthritis by modulating the inflammatory T cell responses","volume":"10","author":"Lee","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102645_bb0335","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102645_bb0340","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2010.143","article-title":"The yin and yang of regulatory T cells and inflammation in RA","volume":"6","author":"Notley","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0345","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2020.102645_bb0350","doi-asserted-by":"crossref","first-page":"7103219","DOI":"10.1155\/2018\/7103219","article-title":"The proportion of regulatory T cells in patients with systemic lupus erythematosus: a meta-analysis","volume":"2018","author":"Zhang","year":"2018","journal-title":"J Immunol Res"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162306","article-title":"The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-analysis","volume":"11","author":"Morita","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0360","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00296-011-1984-x","article-title":"Disturbed Th17\/Treg balance in patients with rheumatoid arthritis","volume":"32","author":"Niu","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010134","article-title":"Therapeutic potential of targeting the Th17\/Treg axis in autoimmune disorders","volume":"22","author":"Fasching","year":"2017","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0370","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrrheum.2014.105","article-title":"TREG-cell therapies for autoimmune rheumatic diseases","volume":"10","author":"Miyara","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"730","key":"10.1016\/j.autrev.2020.102645_bb0375","article-title":"The balance of Th17 versus treg cells in autoimmunity","volume":"19","author":"Lee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0380","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","article-title":"Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation","volume":"26","author":"Laurence","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2020.102645_bb0385","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-065X.2011.01004.x","article-title":"T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells","volume":"241","author":"Cheng","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2020.102645_bb0390","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.immuni.2006.07.011","article-title":"Transforming growth factor-b controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms","volume":"25","author":"Li","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2020.102645_bb0395","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature."},{"issue":"7090","key":"10.1016\/j.autrev.2020.102645_bb0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0405","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1002\/art.34601","article-title":"Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells","volume":"64","author":"Ju","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0410","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni.1995","article-title":"Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5","volume":"12","author":"Yang","year":"2011","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0415","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4049\/jimmunol.1602060","article-title":"FOXP3, the transcription factor at the heart of the rebirth of immune tolerance","volume":"198","author":"Bluestone","year":"2017","journal-title":"The Journal of Immunology"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0420","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0425","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0430","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ni1179","article-title":"A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"issue":"21","key":"10.1016\/j.autrev.2020.102645_bb0435","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0440","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2018.10.010","article-title":"Hippo kinases Mst1 and Mst2 sense and amplify IL-2R-STAT5 signaling in regulatory T cells to establish stable regulatory activity","volume":"49","author":"Shi","year":"2018","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0445","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0450","article-title":"Interleukin-2 and STAT5 in regulatory T cell development and function","volume":"2","author":"Mahmud","year":"2013","journal-title":"JAKSTAT"},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0455","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0460","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102645_bb0465","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.2426","article-title":"Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions","volume":"17","author":"Chung","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2020.102645_bb0470","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.immuni.2008.05.009","article-title":"Generation of T follicular helper cells is mediated by Interleukin-21 but independent of T helper 1, 2, or 17 cell lineages","volume":"29","author":"Nurieva","year":"2008","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0475","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4110\/in.2014.14.1.21","article-title":"Insights into the role of follicular helper T cells in autoimmunity","volume":"14","author":"Park","year":"2014","journal-title":"Immune Netw"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0480","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.autrev.2020.102645_bb0485","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm.2425","article-title":"Foxp3+ follicular regulatory T cells control the germinal center response","volume":"17","author":"Linterman","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0490","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.it.2015.05.005","article-title":"T follicular regulatory cells in the regulation of B cell responses","volume":"36","author":"Sage","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2020.102645_bb0495","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imr.12411","article-title":"T follicular regulatory cells","volume":"271","author":"Sage","year":"2016","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.autrev.2020.102645_bb0500","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41584-019-0254-2","article-title":"T follicular helper cells and T follicular regulatory cells in rheumatic diseases","volume":"15","author":"Deng","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0505","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0510","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri2637","article-title":"Dysregulation of germinal centres in autoimmune disease","volume":"9","author":"Vinuesa","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0515","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1084\/jem.192.11.1545","article-title":"Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production","volume":"192","author":"Breitfeld","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2020.102645_bb0520","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0525","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/08916934.2017.1284821","article-title":"Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity","volume":"50","author":"Qiu","year":"2017","journal-title":"Autoimmunity."},{"issue":"5943","key":"10.1016\/j.autrev.2020.102645_bb0530","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.1176676","article-title":"Bcl6 mediates the development of T follicular helper cells","volume":"325","author":"Nurieva","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0535","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4049\/jimmunol.0904023","article-title":"In vivo regulation of Bcl6 and T follicular helper cell development","volume":"185","author":"Poholek","year":"2010","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0540","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-018-1690-0","article-title":"Enhanced IL-6\/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper\/T follicular regulatory cells in patients with rheumatoid arthritis","volume":"20","author":"Niu","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017739","article-title":"IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation","volume":"6","author":"Eto","year":"2011","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0550","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.immuni.2008.06.001","article-title":"A fundamental role for interleukin-21 in the generation of T follicular helper cells","volume":"29","author":"Vogelzang","year":"2008","journal-title":"Immunity"},{"issue":"5943","key":"10.1016\/j.autrev.2020.102645_bb0555","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1175870","article-title":"Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation","volume":"325","author":"Johnston","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0560","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4049\/jimmunol.178.1.242","article-title":"Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production","volume":"178","author":"Gong","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0565","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1084\/jem.20111174","article-title":"STAT5 is a potent negative regulator of TFH cell differentiation","volume":"209","author":"Johnston","year":"2012","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0570","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.immuni.2011.03.023","article-title":"ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6","volume":"34","author":"Choi","year":"2011","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0575","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2011.09.009","article-title":"Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells","volume":"35","author":"Pepper","year":"2011","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0580","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2015.08.017","article-title":"The Interleukin-2-mTORc1 kinase Axis defines the Signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells","volume":"43","author":"Ray","year":"2015","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0585","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.immuni.2017.08.011","article-title":"The kinase mTORC1 promotes the generation and suppressive function of follicular regulatory T cells","volume":"47","author":"Xu","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0590","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0595","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102645_bb0600","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR Signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2020.102645_bb0605","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.1038\/ncomms10579","article-title":"Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells","volume":"7","author":"Aloulou","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0610","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12739","article-title":"T follicular regulatory (Tfr) cells: dissecting the complexity of Tfr-cell compartments","volume":"288","author":"Fonseca","year":"2019","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0615","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.immuni.2017.11.008","article-title":"Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of Treg to Tfr cells","volume":"47","author":"Essig","year":"2017","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0620","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/ni.3837","article-title":"Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection","volume":"18","author":"Botta","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2020.102645_bb0625","doi-asserted-by":"crossref","first-page":"827480","DOI":"10.1155\/2012\/827480","article-title":"Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis","volume":"2012","author":"Ma","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0630","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s10067-015-3028-5","article-title":"Follicular helper T cells in rheumatoid arthritis","volume":"34","author":"Yu","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0635","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/ni.3578","article-title":"Suppression by TFR cells leads to durable and selective inhibition of B cell effector function","volume":"17","author":"Sage","year":"2016","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0640","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.acthis.2013.10.009","article-title":"A preliminary study on the characterization of follicular helper T (Tfh) cells in rheumatoid arthritis synovium","volume":"116","author":"Chu","year":"2014","journal-title":"Acta Histochem"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0645","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/art.40664","article-title":"T follicular regulatory cells are decreased in patients with established treated rheumatoid arthritis with active disease: comment on the article by Liu et al","volume":"70","author":"Chang","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2020.102645_bb0650","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/art.38735","article-title":"Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice","volume":"66","author":"Ding","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0655","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.40430","article-title":"Increased circulating follicular Treg cells are associated with lower levels of autoantibodies in patients with rheumatoid arthritis in stable remission","volume":"70","author":"Liu","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0660","article-title":"Regulation of autoimmune germinal center reactions in lupus-prone BXD2 mice by follicular helper T cells","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One."},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0665","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/imt.14.83","article-title":"Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases","volume":"6","author":"Ballesteros-Tato","year":"2014","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0670","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2012.02.012","article-title":"Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation","volume":"36","author":"Ballesteros-Tato","year":"2012","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.autrev.2020.102645_bb0675","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1093\/rheumatology\/keq250","article-title":"Improved treatment strategies reduce the increased mortality risk in early RA patients","volume":"49","author":"JAB","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"10086","key":"10.1016\/j.autrev.2020.102645_bb0680","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"The Lancet."},{"issue":"3","key":"10.1016\/j.autrev.2020.102645_bb0685","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10067-017-3850-z","article-title":"Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study","volume":"37","author":"Zhu","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102645_bb0690","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/1756-185X.12211","article-title":"A study on relationship among apoptosis rates, number of peripheral T cell subtypes and disease activity in rheumatoid arthritis","volume":"19","author":"Ji","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0695","doi-asserted-by":"crossref","first-page":"102421","DOI":"10.1016\/j.autrev.2019.102421","article-title":"The giants (biologicals) against the pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0700","doi-asserted-by":"crossref","first-page":"102399","DOI":"10.1016\/j.autrev.2019.102399","article-title":"Can we wean patients with inflammatory arthritis from biological therapies?","volume":"18","author":"Edwards","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"18","key":"10.1016\/j.autrev.2020.102645_bb0705","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0710","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","article-title":"A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells","volume":"30","author":"Yu","year":"2009","journal-title":"Immunity."},{"issue":"12","key":"10.1016\/j.autrev.2020.102645_bb0715","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102645_bb0720","first-page":"1","article-title":"Circulating regulatory T cells were absolutely decreased in dermatomyositis\/polymyositis patients and restored by low-dose IL-2","volume":"0","author":"Zhang","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2020.102645_bb0725","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10753-014-9987-x","article-title":"Exogenous IL-2 controls the balance in Th1, Th17, and Treg cell distribution in patients with progressive rheumatoid arthritis treated with TNF-alpha inhibitors","volume":"38","author":"Kosmaczewska","year":"2015","journal-title":"Inflammation"},{"issue":"5769","key":"10.1016\/j.autrev.2020.102645_bb0730","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.autrev.2020.102645_bb0735","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.intimp.2019.03.064","article-title":"New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases","volume":"72","author":"Xu","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"26","key":"10.1016\/j.autrev.2020.102645_bb0740","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2020.102645_bb0745","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective Interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0750","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20082824","article-title":"In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression","volume":"206","author":"Webster","year":"2009","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.autrev.2020.102645_bb0755","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/eji.200939792","article-title":"Expansion of regulatory T cells via IL-2\/anti-IL-2 mAb complexes suppresses experimental myasthenia","volume":"40","author":"Liu","year":"2010","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0760","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.4049\/jimmunol.1701502","article-title":"IL-2-anti-IL-2 monoclonal antibody immune complexes inhibit collagen-induced arthritis by augmenting regulatory T cell functions","volume":"201","author":"Yokoyama","year":"2018","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102645_bb0765","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/imm.12008","article-title":"Interleukin-2\/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2\/STAT5 signalling pathways","volume":"137","author":"Lee","year":"2012","journal-title":"Immunology."},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0770","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to Interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity."},{"issue":"5","key":"10.1016\/j.autrev.2020.102645_bb0775","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1073\/pnas.0909384107","article-title":"IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25","volume":"107","author":"Letourneau","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2020.102645_bb0780","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4161\/mabs.27224","article-title":"Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects","volume":"6","author":"Rojas","year":"2014","journal-title":"MAbs."},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0785","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.autrev.2020.102645_bb0790","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.4049\/jimmunol.1800578","article-title":"Engineering a single-agent cytokine\/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy","volume":"201","author":"Spangler","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102645_bb0795","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14712598.6.12.1323","article-title":"Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease","volume":"6","author":"Onur","year":"2006","journal-title":"Expert Opin. Biol. Ther"},{"key":"10.1016\/j.autrev.2020.102645_bb0800","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0162-3109(94)90058-2","article-title":"An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2","volume":"28","author":"Courtney","year":"1994","journal-title":"Immunopharmacology."},{"key":"10.1016\/j.autrev.2020.102645_bb0805","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/81199","article-title":"A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo","volume":"18","author":"Shanafelt","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2020.102645_bb0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease","volume":"95","author":"Peterson","year":"2018","journal-title":"J Autoimmun"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:19Z","timestamp":1761600139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220302160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":162,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1568997220302160"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102645","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102645"}}